Tagrisso (osimertinib) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity against central nervous system (CNS) metastases. Tagrisso is indicated for 1st-line use in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) and for patients with EGFR T790M mutation-positive advanced NSCLC.

Product Information – European Medicines Agency